Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany

Johanna Koehler, Barbara Ritzer, Simon Weidlich, Friedemann Gebhardt, Chlodwig Kirchhoff, Jens Gempt, Christiane Querbach, Dieter Hoffmann, Bernhard Haller, Roland M. Schmid, Jochen Schneider, Christoph D. Spinner, Roman Iakoubov

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.

Original languageEnglish
Pages (from-to)1313-1318
Number of pages6
JournalInfection
Volume49
Issue number6
DOIs
StatePublished - Dec 2021
Externally publishedYes

Keywords

  • Bamlanivimab
  • COVID-19
  • Casirivimab
  • Imdevimab
  • Monoclonal spike antibodies
  • SARS-CoV2

Fingerprint

Dive into the research topics of 'Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany'. Together they form a unique fingerprint.

Cite this